The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Remicade (infliximab) Drug-Global Market Insights and Sales Trends 2024
Synopsis
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Remicade (infliximab) Drug market size is expected to reach US$ 3855 million by 2029, growing at a CAGR of 5.6% from 2023 to 2029. The market is mainly driven by the significant applications of Remicade (infliximab) Drug in various end use industries. The expanding demands from the Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis and Pediatric Ulcerative Colitis, are propelling Remicade (infliximab) Drug market. Brands Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Remicade (infliximab) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Remicade (infliximab) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Remicade (infliximab) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Remicade (infliximab) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Remicade (infliximab) Drug covered in this report include J & J, Pfizer, Celltrion Healthcare, Epirus Biopharmaceuticals and Samsung Bioepsis, etc.
The global Remicade (infliximab) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
J & J
Pfizer
Celltrion Healthcare
Epirus Biopharmaceuticals
Samsung Bioepsis
Global Remicade (infliximab) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Remicade (infliximab) Drug market, Segment by Type:
Brands Drugs
Generic Drugs
Global Remicade (infliximab) Drug market, by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Remicade (infliximab) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Remicade (infliximab) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Remicade (infliximab) Drug market size is expected to reach US$ 3855 million by 2029, growing at a CAGR of 5.6% from 2023 to 2029. The market is mainly driven by the significant applications of Remicade (infliximab) Drug in various end use industries. The expanding demands from the Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis and Pediatric Ulcerative Colitis, are propelling Remicade (infliximab) Drug market. Brands Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Remicade (infliximab) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Remicade (infliximab) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Remicade (infliximab) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Remicade (infliximab) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Remicade (infliximab) Drug covered in this report include J & J, Pfizer, Celltrion Healthcare, Epirus Biopharmaceuticals and Samsung Bioepsis, etc.
The global Remicade (infliximab) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
J & J
Pfizer
Celltrion Healthcare
Epirus Biopharmaceuticals
Samsung Bioepsis
Global Remicade (infliximab) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Remicade (infliximab) Drug market, Segment by Type:
Brands Drugs
Generic Drugs
Global Remicade (infliximab) Drug market, by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Remicade (infliximab) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Remicade (infliximab) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Remicade (infliximab) Drug Market Overview
1.1 Remicade (infliximab) Drug Product Overview
1.2 Remicade (infliximab) Drug Market Segment by Type
1.2.1 Brands Drugs
1.2.2 Generic Drugs
1.3 Global Remicade (infliximab) Drug Market Size by Type
1.3.1 Global Remicade (infliximab) Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Remicade (infliximab) Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Remicade (infliximab) Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Remicade (infliximab) Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Remicade (infliximab) Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Remicade (infliximab) Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Remicade (infliximab) Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Remicade (infliximab) Drug Sales Breakdown by Type (2018-2023)
2 Global Remicade (infliximab) Drug Market Competition by Company
2.1 Global Top Players by Remicade (infliximab) Drug Sales (2018-2023)
2.2 Global Top Players by Remicade (infliximab) Drug Revenue (2018-2023)
2.3 Global Top Players by Remicade (infliximab) Drug Price (2018-2023)
2.4 Global Top Manufacturers Remicade (infliximab) Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Remicade (infliximab) Drug Market Competitive Situation and Trends
2.5.1 Remicade (infliximab) Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Remicade (infliximab) Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Remicade (infliximab) Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Remicade (infliximab) Drug Market
2.8 Key Manufacturers Remicade (infliximab) Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Remicade (infliximab) Drug Status and Outlook by Region
3.1 Global Remicade (infliximab) Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Remicade (infliximab) Drug Historic Market Size by Region
3.2.1 Global Remicade (infliximab) Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Remicade (infliximab) Drug Sales in Value by Region (2018-2023)
3.2.3 Global Remicade (infliximab) Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Remicade (infliximab) Drug Forecasted Market Size by Region
3.3.1 Global Remicade (infliximab) Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Remicade (infliximab) Drug Sales in Value by Region (2024-2029)
3.3.3 Global Remicade (infliximab) Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Remicade (infliximab) Drug by Application
4.1 Remicade (infliximab) Drug Market Segment by Application
4.1.1 Crohn's Disease
4.1.2 Pediatric Crohn's Disease
4.1.3 Ulcerative Colitis
4.1.4 Pediatric Ulcerative Colitis
4.1.5 Other
4.2 Global Remicade (infliximab) Drug Market Size by Application
4.2.1 Global Remicade (infliximab) Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Remicade (infliximab) Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Remicade (infliximab) Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Remicade (infliximab) Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Remicade (infliximab) Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Remicade (infliximab) Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Remicade (infliximab) Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Remicade (infliximab) Drug Sales Breakdown by Application (2018-2023)
5 North America Remicade (infliximab) Drug by Country
5.1 North America Remicade (infliximab) Drug Historic Market Size by Country
5.1.1 North America Remicade (infliximab) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Remicade (infliximab) Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Remicade (infliximab) Drug Sales in Value by Country (2018-2023)
5.2 North America Remicade (infliximab) Drug Forecasted Market Size by Country
5.2.1 North America Remicade (infliximab) Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Remicade (infliximab) Drug Sales in Value by Country (2024-2029)
6 Europe Remicade (infliximab) Drug by Country
6.1 Europe Remicade (infliximab) Drug Historic Market Size by Country
6.1.1 Europe Remicade (infliximab) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Remicade (infliximab) Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Remicade (infliximab) Drug Sales in Value by Country (2018-2023)
6.2 Europe Remicade (infliximab) Drug Forecasted Market Size by Country
6.2.1 Europe Remicade (infliximab) Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Remicade (infliximab) Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Remicade (infliximab) Drug by Region
7.1 Asia-Pacific Remicade (infliximab) Drug Historic Market Size by Region
7.1.1 Asia-Pacific Remicade (infliximab) Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Remicade (infliximab) Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Remicade (infliximab) Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Remicade (infliximab) Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Remicade (infliximab) Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Remicade (infliximab) Drug Sales in Value by Region (2024-2029)
8 Latin America Remicade (infliximab) Drug by Country
8.1 Latin America Remicade (infliximab) Drug Historic Market Size by Country
8.1.1 Latin America Remicade (infliximab) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Remicade (infliximab) Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Remicade (infliximab) Drug Sales in Value by Country (2018-2023)
8.2 Latin America Remicade (infliximab) Drug Forecasted Market Size by Country
8.2.1 Latin America Remicade (infliximab) Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Remicade (infliximab) Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Remicade (infliximab) Drug by Country
9.1 Middle East and Africa Remicade (infliximab) Drug Historic Market Size by Country
9.1.1 Middle East and Africa Remicade (infliximab) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Remicade (infliximab) Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Remicade (infliximab) Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Remicade (infliximab) Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Remicade (infliximab) Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Remicade (infliximab) Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 J & J
10.1.1 J & J Company Information
10.1.2 J & J Introduction and Business Overview
10.1.3 J & J Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 J & J Remicade (infliximab) Drug Products Offered
10.1.5 J & J Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Remicade (infliximab) Drug Products Offered
10.2.5 Pfizer Recent Development
10.3 Celltrion Healthcare
10.3.1 Celltrion Healthcare Company Information
10.3.2 Celltrion Healthcare Introduction and Business Overview
10.3.3 Celltrion Healthcare Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Celltrion Healthcare Remicade (infliximab) Drug Products Offered
10.3.5 Celltrion Healthcare Recent Development
10.4 Epirus Biopharmaceuticals
10.4.1 Epirus Biopharmaceuticals Company Information
10.4.2 Epirus Biopharmaceuticals Introduction and Business Overview
10.4.3 Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Epirus Biopharmaceuticals Remicade (infliximab) Drug Products Offered
10.4.5 Epirus Biopharmaceuticals Recent Development
10.5 Samsung Bioepsis
10.5.1 Samsung Bioepsis Company Information
10.5.2 Samsung Bioepsis Introduction and Business Overview
10.5.3 Samsung Bioepsis Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Samsung Bioepsis Remicade (infliximab) Drug Products Offered
10.5.5 Samsung Bioepsis Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Remicade (infliximab) Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Remicade (infliximab) Drug Industrial Chain Analysis
11.4 Remicade (infliximab) Drug Market Dynamics
11.4.1 Remicade (infliximab) Drug Industry Trends
11.4.2 Remicade (infliximab) Drug Market Drivers
11.4.3 Remicade (infliximab) Drug Market Challenges
11.4.4 Remicade (infliximab) Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Remicade (infliximab) Drug Distributors
12.3 Remicade (infliximab) Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
